default author photo

Chiara Braconi

University of Glasgow - Institute of Cancer Sciences

Glasgow, Scotland G12 8LE

United Kingdom

SCHOLARLY PAPERS

3

DOWNLOADS

196

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A Large Real-Life Worldwide Population

Number of pages: 28 Posted: 15 May 2024
Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Universita di Cagliari - University Hospital of Cagliari, Careggi University Hospital of Florence - Clinical Oncology Unit, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, affiliation not provided to SSRN, KU Leuven, University of Pisa, IRCCS Humanitas Research Hospital, Università Campus Bio-Medico di Roma, Seoul National University - Seoul National University Bundang Hospital, Mayo Clinic, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), AUSL Romagna - Oncology Unit, Boston Consulting Group - Berlin, University of Foggia, Fondazione IRCCS Istituto Nazionale dei Tumori, CHA University - CHA Bundang Medical Center, University of Glasgow - Institute of Cancer Sciences, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Ulsan - Department of Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Universita di Cagliari - University Hospital of Cagliari, Medical University of Vienna, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ulm University - Ulm University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, San Luigi Gonzaga University Hospital, The Chinese University of Hong Kong (CUHK) - Department of Clinical Oncology, affiliation not provided to SSRN, IRCCS Humanitas Research Hospital, University of Parma, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa, affiliation not provided to SSRN, AOU Careggi, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, National Cancer Center Hospital East, KU Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, Istituto Clinico Humanitas, Campus Bio-Medico University, Seoul National University - Seoul National University Hospital, Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, affiliation not provided to SSRN, University of Pisa - Department of Translational Research and of New Surgical and Medical Technologies, University Hospital Frankfurt, University of Foggia, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), IRCCS Humanitas Research Hospital and Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele
Downloads 75 (837,727)

Abstract:

Loading...

cholangiocarcinoma, durvalumab, immunotherapy, real-world evidence, biliary tract cancer, advanced disease

2.

Presentation, Management and Outcome of Cholangiocarcinoma in Europe: Results From Real-World Patient Registry

Number of pages: 75 Posted: 25 May 2021
Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, The Christie NHS Foundation Trust - Department of Medical Oncology, Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, Erasmus MC University Medical Center - Department of Surgery, University of Regensburg - Institute of Pathology, University of Amsterdam - Cancer Center Amsterdam, Department of Medical Oncology, Hospital Universitario 12 de Octubre - Department of Medical Oncology, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Humanitas University - Division of Internal Medicine and Hepatology, University of Padua - DMM Department of Molecular Medicine, Universidad de Navarra - Clinica Universidad de Navarra and Program in Solid Tumors (CIMA), Sorbonne Université - Department of Hepatobiliary and Liver Transplantation Surgery, Sapienza University of Rome - Translational and Precision Medicine, University of Glasgow - Institute of Cancer Sciences, University of Sassari - Department of Medical, Surgical and Experimental Sciences, University of Glasgow - Institute of Cancer Sciences, Carlos III National Institute of Health - Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Klinik Favoriten - Department for Surgery, Università Politecnica delle Marche - Department of Gastroenterology, Medical University of Warsaw - Department of General, Transplant and Liver Surgery, Oslo University Hospital Rikshospitalet - Norwegian PSC Research Center, Department of Transplantation Medicine, Lithuanian University of Health Sciences - Department of Gastroenterology and Institute for Digestive Research, University of Medicine and Pharmacy - Institute for Gastroenterology and Hepatology, 3rd Medical Department, Saarland University - Department of Medicine II, Teaching Hospital No. 1 - of Gastroenterology and Hepatology with General Medicine Unit, Grigore T. Popa University of Medicine and Pharmacy - Department of Morpho-Functional Sciences I, Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, Erasmus MC University Medical Center - Department of Surgery, University of Regensburg - Institute of Pathology, University of Amsterdam - Department of Surgery, Hospital Universitario 12 de Octubre - Department of Medical Oncology, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, University of Regensburg - Institute of Pathology, Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, Sapienza University of Rome - Department of Movement, Human and Health Sciences, University of Copenhagen - Biotech Research and Innovation Centre, University of Salamanca - Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, Sapienza University of Rome - Translational and Precision Medicine, Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, Instituto de Salud Carlos III” (ISCIII) - National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, The Christie NHS Foundation Trust - Department of Medical Oncology, Erasmus University Rotterdam (EUR) - Department of Surgery and University of the Basque Country - Department of Liver and Gastrointestinal Diseases
Downloads 70 (875,328)

Abstract:

Loading...

cholangiocarcinoma; International Classification of Diseases 11th edition (ICD-11); subtypes; diagnosis; risk factors; treatment; prognosis

3.

Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy

Number of pages: 31 Posted: 03 Dec 2024
Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, University of Pisa, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Universita di Cagliari - University Hospital of Cagliari, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Careggi University Hospital of Florence - Clinical Oncology Unit, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, affiliation not provided to SSRN, KU Leuven, University of Pisa, affiliation not provided to SSRN, University of Florida, Università Campus Bio-Medico di Roma, Mayo Clinic, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), affiliation not provided to SSRN, AUSL Romagna - Oncology Unit, Boston Consulting Group - Berlin, University of Foggia, Fondazione IRCCS Istituto Nazionale dei Tumori, CHA University - CHA Bundang Medical Center, University of Glasgow - Institute of Cancer Sciences, University of Glasgow, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Ulsan - Department of Oncology, Polytechnic University of Marche, affiliation not provided to SSRN, Universita di Cagliari - University Hospital of Cagliari, Medical University of Vienna, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ulm University - Ulm University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, San Luigi Gonzaga University Hospital, The Chinese University of Hong Kong (CUHK) - Department of Clinical Oncology, affiliation not provided to SSRN, IRCCS Humanitas Research Hospital, University of Parma, affiliation not provided to SSRN, affiliation not provided to SSRN, Hospital de Santa Maria, affiliation not provided to SSRN, University of Padua, Humanitas University, affiliation not provided to SSRN, AOU Careggi, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, National Cancer Center Hospital East, KU Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Campus Bio-Medico University, Seoul National University - Seoul National University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Foggia, affiliation not provided to SSRN, Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, University of Pisa, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Vita Salute San Raffaele University, IRCCS Humanitas Research Hospital and Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele
Downloads 51 (1,052,702)

Abstract:

Loading...

Biliary Tract Cancer, gut micobiome, antibiotic therapy, Immune checkpoint inhibitors